This study examines the effectiveness of olaparib in treating cholangiocarcinoma, glioma, and solid tumors which have mutations in the IDH1 or IDH2 gene; unable to treat or control with current treatments; have migrated to other parts of the body. This evidence concerns the gene IDH1 and cholangiocarcinoma.